Lesson plan
Ocedurenone
Ocedurenone, formerly known as KBP-5074, is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments. In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for up to USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.
Article summary
Ocedurenone, formerly known as KBP-5074, is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments. In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for up to USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.